A pilot study of low-dose erythromycin in bronchiectasis

Area of Science:

• Pulmonology
• Pharmacology

Background:

• Bronchiectasis is characterized by persistent sputum, frequent exacerbations, and progressive airway damage.
• Erythromycin's efficacy in diffuse panbronchiolitis suggests potential utility in other suppurative airway diseases like bronchiectasis.

Purpose of the Study:

• To evaluate the effects of low-dose erythromycin on lung function and sputum production in patients with idiopathic bronchiectasis.
• To assess changes in inflammatory markers and sputum pathogens following erythromycin treatment.

Main Methods:

• A double-blind, placebo-controlled study involving 8-week administration of low-dose erythromycin (500 mg twice daily).
• Participants included patients with steady-state idiopathic bronchiectasis (n=11 erythromycin, n=10 placebo).
• Measurements included lung function (forced expiratory volume in one second, forced vital capacity) and 24-hour sputum volume.

Main Results:

• The erythromycin group showed significant improvements in forced expiratory volume in one second, forced vital capacity, and 24-hour sputum volume compared to placebo (p<0.05).
• No significant changes were observed in sputum pathogens, leukocytes, or inflammatory mediators (IL-1α, IL-8, TNF-α, LTB4).

Conclusions:

• Low-dose erythromycin administration for eight weeks improved lung function and reduced sputum volume in patients with idiopathic bronchiectasis.
• Further research is warranted to explore the long-term efficacy of erythromycin therapy for bronchiectasis.